Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback